



Principal Pharmaceuticals & Chemicals Ltd.

513, Palm Spring, Link Road, Malad West, Mumbai - 400 064

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2012

PRINCIPAL

Rs. In lacs except EPS


PART I

Sr. No.	3 Months ended 31st Dec, 2012 Un-Audited	3 Months ended 30th Sept, 2012 Un-Audited	3 Months ended 31st Dec, 2011 Un-Audited	9 Months ended 31st Dec, 2012 Un-Audited	9 Months ended 31st Dec, 2011 Un-Audited	Year ended 31st March, 2012 Audited
1 Income from Operations						
a. Net Sales/ Income from Operations	7.95	13.79	5.55	26.70	14.55	19.52
b. Other Operating Income	12.70	0.14	-	12.84	0.08	0.21
Total Income from operations	20.65	13.93	5.55	39.54	14.63	19.73
2 Expenses						
a. (Increase)/decrease in stock trade	-	-	-	-	-	-
b. Consumption of raw materials / Purchases	2.29	7.14	-	9.43	-	-
c. Staff Cost	1.50	1.50	0.37	4.50	1.12	1.50
d. Power & Fuel & Oil	-	-	-	-	-	-
e. Job processing charges	-	-	-	-	-	-
f. Internet Business Development Cost	-	-	-	-	-	-
g. Other expenditure	2.22	0.74	1.00	4.57	6.31	10.08
Total Expenses before depreciation, amortization, finance cost, extraordinary items and tax	6.01	9.38	1.37	18.50	7.43	11.58
3 Interest	-	-	-	-	-	-
4 Depreciation & Amortisation	2.80	2.89	(10.02)	8.63	8.67	10.23
5 Profit/(Loss) before tax and extraordinary items (1-2-3-4)	11.84	1.66	14.20	12.41	(1.47)	(2.08)
Less :						
6 Provision for taxation						
- Current Year Tax	-	-	-	-	-	-
- Deferred Tax	-	-	-	-	-	-
7 Net Profit/(Loss) before extraordinary items (5-6)	11.84	1.66	14.20	12.41	(1.47)	(2.08)
Extraordinary Items:						
8 Relisting Fee	-	-	-	-	(4.80)	(4.80)
9 Expenses for reduction of capital and new allotment	-	(1.80)	-	(1.80)	-	-
10 Net Profit/(Loss) for the period	11.84	(0.14)	14.20	10.61	(6.27)	(6.88)
11 Paid-up equity share capital	795.00	434.96	599.97	795.00	599.97	434.96
(Face value Rs. 10 each upto 30th March 2012. Post Reduction Face Value is reduced to Rs. 4/- each wef 31st March, 2012)						
12 Reserve excluding revaluation reserves						(336.94)
(Net of debit balance of Profit & Loss Account)						
13 Basic & diluted EPS for the period, for the year to date & for the previous year (prior to extra ordinary item) (not to be annualised)	0.07	0.02	0.24	0.09	(0.02)	(0.03)
14 Basic & diluted EPS for the period, for the year to date & for the previous year (after extra ordinary item) (not to be annualised)	0.07	(0.00)	0.24	0.08	(0.10)	(0.11)

SELECT INFORMATION FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2012

PART II

1 Aggregate of Non-Promoters' Shareholding						
No. of shares (in lacs)	79.97	40.79	40.79	79.97	40.79	40.79
Percentage of Shareholding	40.24%	37.51%	67.99%	40.24%	67.99%	37.51%
2 Promoters and Promoter Group Shareholding						
a. Pledged /Encumbered						
- No. of Shares (in lacs)	-	-	-	-	-	-
- Percentage of Shares (as a % of total shareholding of promoter and promoter group)	-	-	-	-	-	-
- Percentage of Shares (as a % of total sharecapital of the company)	-	-	-	-	-	-
b. Non - Encumbered						
- No. of Shares (in lacs)	118.78	67.95	19.21	118.78	19.21	67.95
- Percentage of Shares (as a % of total shareholding of promoter and promoter group)	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
- Percentage of Shares (as a % of total sharecapital of the company)	59.76%	62.49%	32.01%	59.76%	32.01%	62.49%






PRINCIPAL

	3 Months ended 31st Dec, 2012	3 Months ended 30th Sept, 2012	3 Months ended 31st Dec, 2011	9 Months ended 31st Dec, 2012	9 Months ended 31st Dec, 2011	Year ended 31st March, 2012
I SEGMENT REVENUE	Un-Audited	Un-Audited	Un-Audited	Un-Audited	Un-Audited	Audited
i. Digital and eCommerce	11.71	8.83	-	20.55	-	-
ii. Pharmaceuticals & Intermediates	8.94	5.10	5.55	18.99	14.63	19.73
TOTAL INCOME FROM OPERATIONS	20.65	13.93	5.55	39.54	14.63	19.73
II SEGMENT RESULT						
PROFIT/(LOSS) BEFORE TAX AND EXTRAORDINARY ITEMS						
i. Digital and eCommerce	9.31	1.60	-	10.92	-	-
ii. Pharmaceuticals & Intermediates	2.52	0.06	(14.20)	1.49	(6.27)	(2.08)
TOTAL SEGMENT RESULTS	11.83	1.66	(14.20)	12.41	(6.27)	(2.08)
Less:						
i. Interest and other financial charges	-	-	-	-	-	-
ii. Un-allocable Expenditure	-	-	-	-	-	-
TOTAL PROFIT BEFORE TAX AND EXTRAORDINARY ITEM	11.83	1.66	(14.20)	12.41	(6.27)	(2.08)
Less: Extraordinary Item	-	(1.80)	-	(1.80)	-	(4.80)
PROFIT BEFORE TAX	11.83	(0.14)	(14.20)	10.61	(6.27)	(6.88)
III CAPITAL EMPLOYED (Segment Asset - Segment Liabilities)						
i. Digital and eCommerce	360.99	1.26	-	360.99	-	-
ii. Pharmaceuticals & Intermediates	107.67	95.52	96.37	107.67	96.37	98.01
TOTAL CAPITAL EMPLOYED IN SEGMENTS	468.66	96.78	96.37	468.66	96.37	98.01

NOTES:

- 1 In the meeting of the Board of Directors held on 31st May, 2012, the company decided to expand its business activities into Digital and eCommerce space with immediate effect besides the existing business activities of manufacturing APIs & Intermediates. The new business activities are carried out in a new division of the company named 'Inovent Digital' and include, inter alia, online selling, digital marketing, e-commerce and fulfillment services. Segmentwise results have been provided herein. The Board of Directors of the company, in the meeting held on 10th December, 2012 approved an investments upto Rs. 300 lacs, subject to the provisions of the Companies Act, 1956 in Inovent Solutions Ltd. towards expanding its overall eCommerce and Digital marketing business. Accordingly, out of additional capital raised by the company to the extent of Rs. 300 lacs is allocated towards this business initiative. Kindly refer note below for outlook of the Pharmaceutical, API and Intermediate business.
- 2 The new shares allotted on 26th October, 2012 to the Promoters and their Associates have yet to be approved for listing by the Bombay Stock Exchange Ltd. (BSE). However, the company has already made listing application to BSE.
- 3 There were no complaints pending at the beginning of 3rd Quarter. Complaints received during 3rd Quarter - NIL; Complaints solved during 3rd Quarter - NIL; Complaints pending at the end of 3rd Quarter - NIL.
- 4 Previous period / year figures have been regrouped / recast, wherever applicable, to make them comparable.
- 5 The above result has been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on 25th January, 2013. The Statutory Auditors have carried out a limited review of the above results as required under clause 41 of the listing agreement with the stock exchange.

Place : Mumbai
Dated : 25th January, 2013



For and on behalf of the Board of Directors

Pradeep Malu
Director, President & CEO